{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:45Z","timestamp":1761513705073},"reference-count":31,"publisher":"Baishideng Publishing Group Inc.","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i38.10874","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T09:56:02Z","timestamp":1444816562000},"page":"10874","source":"Crossref","is-referenced-by-count":14,"title":["Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies"],"prefix":"10.3748","volume":"21","author":[{"given":"Hyoung Su","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bosch FX, Ribes J, Cl&eacute;ries R, D&iacute;az M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211, v.","DOI":"10.1016\/j.cld.2004.12.009"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006;11:669-679.","DOI":"10.1177\/135965350601100614"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23785"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0508-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2013.19.3.300"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939758"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696.","DOI":"10.1086\/368083"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"ref10","unstructured":"Kim JK, Hwang SG, Park H, Choi HY, Cho HJ, Ko KH, Hong SP, Park PW, Kim NK, Rim KS. [Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. Korean J Hepatol 2005;11:227-242."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.","DOI":"10.1056\/NEJMoa051285"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.","DOI":"10.1056\/NEJMoa051287"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22658"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"ref15","unstructured":"Preda CM, Baicus C, Negreanu L, Tugui L, Olariu SV, Andrei A, Zambatu I, Diculescu MM. Effectiveness of entecavir treatment and predictive factors for virologic response. Rev Esp Enferm Dig 2014;106:305-311."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12036"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000360940000360940"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010S0168-8278(12)00167-5"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9080-3"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23229"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2013.19.3.195"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1988-0"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01742-13AAC.01742-13"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03845-14AAC.03845-14"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.018S0168-8278(11)00788-4"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000360399000360399"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01479.x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.063"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Lee JM, Kim HJ, Park JY, Lee CK, Kim do Y, Kim JK, Lee HW, Paik YH, Lee KS, Han KH. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009;14:705-712.","DOI":"10.1177\/135965350901400507"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.1.41"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i38\/10874.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T04:59:22Z","timestamp":1653281962000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i38\/10874.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i38.10874","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}